--Chairman and CEO Flagg Flanagan Among 100 Most Intriguing Entrepreneurs at 
2021 Builders + Innovators Summit

DiscGenics ( 
https://c212.net/c/link/?t=0&l=en&o=3325236-1&h=3446871833&u=https%3A%2F%2Fwww.discgenics.com%2F&a=DiscGenics 
), Inc., a clinical stage biopharmaceutical company focused on developing 
regenerative cell-based therapies that alleviate pain and restore function in 
patients with degenerative diseases of the spine, today announced that Goldman 
Sachs ( 
https://c212.net/c/link/?t=0&l=en&o=3325236-1&h=380402140&u=https%3A%2F%2Fwww.goldmansachs.com%2Findex.html&a=Goldman+Sachs 
) (NYSE:GS) recognized DiscGenics Chairman and CEO Flagg Flanagan as one of the 
100 Most Intriguing Entrepreneurs of 2021 at its Builders + Innovators Summit 
in Healdsburg, California. 

Photo - https://mma.prnewswire.com/media/1661795/FlaggFlanagan.jpg 
Logo - https://mma.prnewswire.com/media/561675/DiscGenics_Logo.jpg

Goldman Sachs selected Mr. Flanagan as one of 100 entrepreneurs from multiple 
industries to be honored at the two-day event.
 
Mr. Flanagan has over 30 years of experience in the medical device field as an 
entrepreneur, executive and advisor. He has led DiscGenics since its founding 
in 2007 and has overseen its evolution from pre-clinical to clinical phase with 
its first product candidate, IDCT (rebonuputemcel), an injectable disc cell 
therapy, now in clinical trials in the U.S. and Japan for degenerative disc 
disease (DDD).

"I am honored to receive this recognition from Goldman Sachs and to be among 
such an innovative group of entrepreneurs," said Mr. Flanagan. "I am extremely 
proud of our team at DiscGenics and remain incredibly excited about the 
opportunity before us to potentially help millions of patients with 
debilitating back pain." 

Prior to DiscGenics, Mr. Flanagan founded Flanagan Instruments, which he built 
over 24 years into a leading neurosurgical device distribution business before 
selling it to Itochu International in 2005. Mr. Flanagan is currently on the 
boards of TrueDigital Systems, Peleton Medical, Triad Life Sciences, Steribite, 
and the Neurosurgery Research & Education Foundation. He has also served on the 
boards of the Alliance for Regenerative Medicine, as well as TrueVision Systems 
and Image Stream Medical, which were acquired by Alcon and Olympus, 
respectively. 

"Innovation doesn't happen just anywhere; it thrives where there's a wide range 
of thoughts and perspectives," said David M. Solomon, Chairman & CEO of Goldman 
Sachs. "One of our great strengths is our ability to bring together people from 
different walks of life and to spark conversations today that will lead to 
breakthroughs tomorrow. The leaders we've chosen to highlight at our Builders + 
Innovators Summit are truly remarkable, and we are pleased to recognize Flagg 
Flanagan as one of this year's most intriguing entrepreneurs."

In addition to honoring 100 entrepreneurs, the summit consists of general 
sessions and clinics led by seasoned entrepreneurs, academics and business 
leaders as well as resident scholars. 

About DiscGenics
DiscGenics is a privately held, clinical stage biopharmaceutical company 
focused on developing regenerative cell-based therapies that alleviate pain and 
restore function in patients with degenerative diseases of the spine. As the 
only company in the world to develop an allogeneic cell therapy derived from 
intervertebral disc cells to treat diseases of the disc, DiscGenics believes it 
has a unique opportunity to harness the restorative potential of the human body 
to heal millions of patients suffering from the debilitating effects of back 
pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic, 
injectable cell therapy that utilizes biomedically engineered progenitor cells 
derived from intervertebral disc tissue, known as Discogenic Cells, to offer a 
non-surgical, potentially regenerative solution for the treatment of patients 
with mild to moderate degenerative disc disease. For more information, visit: 
https://discgenics.com. 

SOURCE:  DiscGenics, Inc.

Media Contacts: Lindsey Saxon
                lindsey@discgenics.com;
                Colin Novick (Japan)
                colin.lee.novick@cj-partners.com